Navigation Links
Federal Trade Commission Files Complaint Against Par Pharmaceutical Over Court-Approved AndroGel(R) Litigation Settlement
Date:2/2/2009

faith final settlement agreement . . . ." The court's Consent Judgment added that the settlement provided the parties with the "opportunity to more productively use money and other resources that would have been spent in the continued prosecution and defense of this Litigation, to the benefit of the Parties and consumers alike . . . ." Furthermore, in ending the three-year patent litigation in the Northern District of Georgia, the Consent Judgment expressly acknowledged that the settlement enabled generic entry "five years earlier than could be achieved if [the generic companies] were permanently enjoined during the life of the [] patent."

The 2006 Court-Approved Settlement Was Approved Under the Same Eleventh Circuit Law that Rejected the FTC's Schering-Plough Case

In 2001, the FTC brought an enforcement action against Schering-Plough Corporation and Upsher-Smith Laboratories, Inc. in which the FTC's judge concluded that there was nothing anticompetitive about the parties' settlement of patent litigation and entry into contemporaneous business arrangements. Although the FTC reversed the findings of its own administrative law judge, the U.S. Court of Appeals for the Eleventh Circuit vacated the FTC's decision and unanimously held that the final patent settlement agreement complied with the antitrust laws. Schering-Plough Corp. v. FTC, 402 F.3d 1056 (11th Cir. 2005). The Eleventh Circuit sits in Atlanta, Georgia, and the U.S. District Court for the Northern District of Georgia is located within the Eleventh Circuit.

Since 2005, the Eleventh Circuit's Schering-Plough decision has been followed by numerous federal circuit and district courts, including by the Second Circuit in In re Tamoxifen Citrate Antitrust Litigation, 466 F.3d 187 (2d Cir. 2006), and by the Federal Circuit in In re Ciprofloxacin Hydrochloride Antitrust Litigation, 544 F.3d 132
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Watson Acknowledges Federal Trade Commission Action Regarding AndroGel Patent Settlement
2. U.S. Senate Acts to Protect Kids, Save Lives by Increasing Federal Tobacco Taxes
3. University of Minnesotas Internationally Recognized Stem Cell Experts Available for Interviews on What Lifting the Federal Funding Restrictions Will Mean to Stem Cell Research and to Patients Who Stand to Benefit
4. UTSA receives federal funding for fossil fuel research
5. ISSA: First Fitness Organization to Earn National Accreditation by a Federally Recognized Accrediting Agency
6. VirtualHealth Technologies, Inc. Unveils Strategy to Leverage $20 Billion Federal Health IT Proposal
7. Federal Members of Advisory Committee Block Vaccine-Autism Research, Defy Wishes of Its Own Scientists, Autism Community, and Congress
8. Eli Lilly Pays a Record $1.4 Billion to Settle Federal and State Fraud Investigations into Illegal Zyprexa Off-Label Marketing Practices
9. U.S. House Acts to Protect Kids, Save Lives by Increasing Federal Tobacco Taxes
10. American Lung Association Report Card Flunks Federal Government and Most States for Neglecting to Prevent Tobacco Caused Illness
11. Zumas Rescue Ranch becomes a Federal 501C3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/13/2014)... 2014 Ticket Down is a ... This beloved pop-rock group that originally formed in 1994 in ... Fans of the group had been anticipating a new album ... were excited yet about the release of their new album, ... announced a massive worldwide tour beginning in the United States ...
(Date:9/13/2014)... 2014 Healthcare employers, hospitals, insurance ... to operators in the Healthcare Consultants ... “Over the past five years, demand for healthcare ... the healthcare sector and the changing regulatory environment,” ... the 2010 Patient Protection and Affordable Care Act ...
(Date:9/13/2014)... 13, 2014 Termlifeinsurancequotesonline.org has released ... life insurance for smokers. , Smokers can now ... a medical examination. The only application process clients have ... answering a few medical questions. , Since smoking ... plans before making a decision. Comparing life insurance policies ...
(Date:9/13/2014)... Researchers say they,ve tracked specific activity in the human ... whether imagination and memory were distinct processes, so a ... to explore the issue. "I was thinking a ... myself in the future, and I started wondering how ... said in a university news release. "I wondered ...
(Date:9/13/2014)... Bedros Keuilian, founder of the internationally franchised Fit Body ... always been an advocate of using Groupon as a marketing ... but the post explains that this isn’t true; but the ... lot of people think of Groupon deals as a way ... special and the only thing they’re thinking of is the ...
Breaking Medicine News(10 mins):Health News:Maroon 5 Tickets Now on Sale in Philadelphia, Washington DC, Nashville, San Jose, Chicago, Dallas, Los Angeles, Tacoma, Saint Paul, Vancouver, San Diego & New York 2Health News:Maroon 5 Tickets Now on Sale in Philadelphia, Washington DC, Nashville, San Jose, Chicago, Dallas, Los Angeles, Tacoma, Saint Paul, Vancouver, San Diego & New York 3Health News:Healthcare Consultants in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Healthcare Consultants in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Smokers Can Qualify for Life Insurance Without Taking a Medical Exam 2Health News:Scientists Watch Imagination at Work in the Brain 2Health News:Renegade Fitness Marketing Expert Reveals How Personal Trainers Can Use Groupon More Effectively to Sign New Clients 2Health News:Renegade Fitness Marketing Expert Reveals How Personal Trainers Can Use Groupon More Effectively to Sign New Clients 3
... (AIs) prevent the conversion of androgens to estrogens, and could ... This study of 36 pre-menopausal women consisted of a cross-over ... wine and white wine in their effects on AIs. ... white wine (or vice versa), each beverage for a one-month ...
... HealthDay Reporter , WEDNESDAY, Jan. 18 (HealthDay News) ... to have successfully cleared the hepatitis C virus in ... more, the approach seems to work without the need ... causes serious side effects in many patients. Scientists ...
... , TUESDAY, Jan. 17 (HealthDay News) -- An experimental anti-blood-clotting ... as Plavix in the days before heart surgery, a new ... to have the potential to serve as a "bridge" medication ... procedures such as coronary artery bypass grafting, the study authors ...
... into the treatment, prognosis and early detection of gastrointestinal ... annual Gastrointestinal Cancers Symposium being held January 19-21, 2012, ... Four important studies were highlighted today in a ... Patients at High Risk for Esophageal Cancer: Newly found ...
... of care advances, more infants and children with ... are left with lifelong neurologic impairment. A ... million pediatric hospitalizations in the U.S. now shows ... small part of the overall population, account for ...
... By Serena Gordon HealthDay Reporter , TUESDAY, Jan. ... one in six American children are obese, new government reports show. ... the past 12 years, those rates have remained roughly the same. ... some time. And, this is not just the U.S. It,s happening ...
Cached Medicine News:Health News:New Drug Combo for Hepatitis C Shows Promise 2Health News:New Drug Combo for Hepatitis C Shows Promise 3Health News:Experimental Blood Thinner Given Before Surgery Shows Benefit 2Health News:2012 Gastroinstestinal Cancers Symposium reveals new advances aimed at improving treatment, prognosis and detection of GI cancers 2Health News:Neurologically impaired children dependent on children's hospitals 2Health News:Americans Aren't Getting Any Skinnier 2Health News:Americans Aren't Getting Any Skinnier 3
(Date:9/14/2014)... , Sept. 14, 2014  Amgen (NASDAQ: AMGN ... S ystolic H eart failure treatment with the ... ivabradine T rial) study evaluating ivabradine in patients with ... Annual Scientific Meeting of the Heart Failure Society of ... post-hoc analysis from the SHIFT study confirmed low systolic blood ...
(Date:9/14/2014)... Sept. 14, 2014  Abbott announced today positive ... first prospective, randomized, controlled trial comparing the safety ... to Abbott,s market-leading metallic XIENCE family of DES.  ... , included 501 people with coronary artery ... disease. The results were featured at a late-breaking ...
(Date:9/13/2014)... , Sept. 13, 2014  Edwards Lifesciences Corporation ... in the science of heart valves and hemodynamic ... outcomes for inoperable patients treated in The PARTNER ... transcatheter aortic valve replacement (TAVR) in patients deemed ... presented as part of the late-breaking clinical trials ...
Breaking Medicine Technology:Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure 2Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure 3Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure 4Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure 5Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure 6Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure 7Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure 8Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure 9ABSORB II Study Shows Abbott's Dissolving Heart Device Comparable to the World's Leading Heart Stent 2ABSORB II Study Shows Abbott's Dissolving Heart Device Comparable to the World's Leading Heart Stent 3ABSORB II Study Shows Abbott's Dissolving Heart Device Comparable to the World's Leading Heart Stent 4ABSORB II Study Shows Abbott's Dissolving Heart Device Comparable to the World's Leading Heart Stent 5Significant Patient Benefits With Edwards Sapien Valve Demonstrated In 5-Year Partner Trial Data 2
... are offered a cost-neutral choice to fill their 90-day ... mail-order pharmacy, they split their preferences largely depending on ... (NYSE: CVS ) has found. ... January edition of the Journal of the American ...
... Wolters Kluwer Health today announced a joint venture with ... decision support to doctors in China as the country ... deal allows Wolters Kluwer Health to expand its market-leading ... the rapidly growing China market and creates a needed ...
Cached Medicine Technology:CVS Caremark Study Evaluates Which Pharmacy Channel Consumers Choose When Given Choice of Mail or Retail Prescriptions 2CVS Caremark Study Evaluates Which Pharmacy Channel Consumers Choose When Given Choice of Mail or Retail Prescriptions 3Wolters Kluwer Health Enters Joint Venture with China Drug Information Provider Medicom 2Wolters Kluwer Health Enters Joint Venture with China Drug Information Provider Medicom 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: